Relapsed/Refractory Primary Central Nervous System Lymphoma Clinical Trials in Pittsburgh, Pennsylvania

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)